Lipocine Advances Phase 3 Trial for PPD Treatment
TipRanks (Tue, 16-Dec 10:19 AM ET)
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
PRNewswire (Tue, 16-Dec 8:00 AM ET)
PRNewswire (Tue, 18-Nov 8:00 AM ET)
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
PRNewswire (Thu, 6-Nov 8:00 AM ET)
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek
PRNewswire (Tue, 4-Nov 8:01 AM ET)
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
PRNewswire (Tue, 30-Sep 8:02 AM ET)
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Lipocine trades on the NASDAQ stock market under the symbol LPCN.
As of December 19, 2025, LPCN stock price climbed to $4.25 with 101,812 million shares trading.
LPCN has a beta of 1.03, meaning it tends to be more sensitive to market movements. LPCN has a correlation of 0.08 to the broad based SPY ETF.
LPCN has a market cap of $23.60 million. This is considered a Sub-Micro Cap stock.
Last quarter Lipocine reported $114,574 in Revenue and -$.59 earnings per share. This fell short of revenue expectation by $-68,226 and missed earnings estimates by -$.04.
In the last 3 years, LPCN traded as high as $11.79 and as low as $2.31.
The top ETF exchange traded funds that LPCN belongs to (by Net Assets): VTI, VXF, DFSU.
LPCN has underperformed the market in the last year with a return of -9.2%, while SPY returned +18.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in LPCN shares. However, LPCN has outperformed the market in the last 3 month and 2 week periods, returning +47.6% and +34.9%, while SPY returned +2.8% and -0.5%, respectively. This indicates LPCN has been having a stronger performance recently.
LPCN support price is $3.97 and resistance is $4.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LPCN shares will trade within this expected range on the day.